Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined. METHODS: We randomly assigned 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors to receive either lorcaserin (10 mg twice daily) or placebo. The primary safety outcome of major cardiovascular events (a composite of cardiovascular death, myocardial infarction, or stroke) was assessed at an interim analysis to exclude a noninferiority boundary of 1.4. If noninferiority was met, the primary cardiovascular efficacy outcome (a composite of major cardiovascular events, heart failure, hospitalization for unstable angina, or coronary revascularization [extended major cardiovascular events]) was assessed for superiority at the end of the trial. RESULTS: At 1 year, weight loss of at least 5% had occurred in 1986 of 5135 patients (38.7%) in the lorcaserin group and in 883 of 5083 (17.4%) in the placebo group (odds ratio, 3.01; 95% confidence interval [CI], 2.74 to 3.30; P<0.001). Patients in the lorcaserin group had slightly better values with respect to cardiac risk factors (including blood pressure, heart rate, glycemic control, and lipids) than those in the placebo group. During a median follow-up of 3.3 years, the rate of the primary safety outcome was 2.0% per year in the lorcaserin group and 2.1% per year in the placebo group (hazard ratio, 0.99; 95% CI, 0.85 to 1.14; P<0.001 for noninferiority); the rate of extended major cardiovascular events was 4.1% per year and 4.2% per year, respectively (hazard ratio, 0.97; 95% CI, 0.87 to 1.07; P=0.55). Adverse events of special interest were uncommon, and the rates were generally similar in the two groups, except for a higher number of patients with serious hypoglycemia in the lorcaserin group (13 vs. 4, P=0.04). CONCLUSIONS: In a high-risk population of overweight or obese patients, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo. (Funded by Eisai; CAMELLIA-TIMI 61 ClinicalTrials.gov number, NCT02019264 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [12]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [8]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [8]
In the citing paper
“lorcaserin, which had a neutral effect on MACEs in the CAMELLIA-TIMI 61 study”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [173]
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Flegal, K. M., Kit, B. K., Orpana, H., & Graubard, B. I. (2013) · JAMA · doi:10.1001/jama.2012.113905 · Cited by 3,998
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Hales, C. M., Fryar, C. D., Carroll, M. D., Freedman, D. S., & Ogden, C. L. (2018) · JAMA · doi:10.1001/jama.2018.3060 · Cited by 1,761
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Cited by
Items 201–267 of 267
Cardiovascular safety of lorcaserin
Lim, G. B. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0092-y · Cited by 1
Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca
Frías, P. T., Ruíz, R. C., Duque, J. A. A., Senén, A. B., Olmo, M. R. F., & Jiménez, M. A. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.01.007 · Cited by 2
Obesity Management and Prevention of Cardiovascular Disease
Gazda, C., & Almandoz, J. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_7 · Cited by 1
Schrader, T. O., Zhu, X., Kasem, M., Ren, A., Liu, C., Wu, C., Dang, H., Le, M., Gatlin, J., Chase, K., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127872 · Cited by 1
Role of SGLT2 inhibitors in the treatment of visceral obesity
Druzhilov, М. A., & Kuznetsova, Т. Y. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2648 · Cited by 1
Abnehmen mit Arzneimitteln? Pharmakotherapie von Übergewicht und Adipositas
Smollich, M. (2021) · Aktuelle Ernährungsmedizin · doi:10.1055/a-1118-2562 · Cited by 1
“Besondere Beachtung fanden dabei die Ergebnisse der CAMELLIA-TIMI-61-Studie mit 5135 Patienten, die im Jahr 2018 publiziert wurden: Ein Gewichtsverlust von mindestens 5% des Ausgangsgewichts nach 1 Jahr erreichten 38% der Patienten der Lorcaserin-Gruppe, aber nur 17% der Placebogruppe (OR 3,01; 95%-KI: 2,7–3,3; p <0,0…”
BackgroundObesity, weight loss and gynecologic neoplasms: a narrative review
Halpern, B., & Mendes, T. B. (2022) · Women & Health · doi:10.1080/03630242.2022.2066747 · Cited by 2
Obesity as a Neurobiologic Disorder: A Heavyweight Contender
Chávez-Castillo, M., Durán, P., Garrido, B., Díaz, A., Escalona, D., & Cano, C. (2022) · Current Psychiatry Research and Reviews · doi:10.2174/2666082218666220527120848 · Cited by 2
A súlyfelesleg és annak csökkentése kardiovaszkuláris szempontból
Bajnok, L. (2021) · Cardiologia Hungarica · doi:10.26430/chungarica.2021.51.5.331 · Cited by 2
Les approches thérapeutiques non invasives de l’obésité : hier, aujourd’hui et demain
Galmiche, M. C., & Déchelotte, P. (2022) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.09.001 · Cited by 2
Central Modulators of Appetite in Eating Disorders
Procházková, P., Roubalová, R., & Papežová, H. (2023) · Springer eBooks · doi:10.1007/978-3-030-97416-9_112-1 · Cited by 2
Mika, K., Szafarz, M., Bednarski, M., Siwek, A., Szczepańska, K., Kieć‐Kononowicz, K., & Kotańska, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087499 · Cited by 2
“Based on the results of a large follow-up safety study [18], lorcaserin appeared to be largely devoid of cardiovascular toxicity.”
ResultDevitt, P., Moran, B., & O’Shea, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-63310-2_2 · Cited by 1
Body shape index: an index for early target organ damage in hypertension
Wei, W., & Ding, P. (2025) · American Journal of Translational Research · doi:10.62347/fmeb5040 · Cited by 1
“Statistics indicate that 75% to 80% of individuals with hypertension are overweight or obese to varying degrees [10].”
Zeng, H., Luo, M., Li, Z., Wen, J., He, G., Jin, Y., Fu, W., & Zhou, P. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029426 · Cited by 2
Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis
Le, L. B., Kullar, R., Saleh, H., & Saab, S. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06382-4 · Cited by 1
Acclaimed anti-obesity drug fails to impress scouts for clinically important research
Kmietowicz, Z. (2019) · BMJ · doi:10.1136/bmj.l464 · Cited by 1
Rubio-Almanza, M. (2019) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14103.2019.664939 · Cited by 2
Hu, C., Li, J., Wu, Y., Wang, M., Tkebuchava, T., & Wu, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-3038479/v1 · Cited by 1
Erstmals bewiesen: eine Abnehmpille ist kardiovaskulär sicher
Overbeck, P. (2018) · CardioVasc · doi:10.1007/s15027-018-1400-5
Warum der Kampf gegen Adipositas oft scheitert
Klein, F. (2018) · CME · doi:10.1007/s11298-018-6827-6
Appetitzügler verringert Diabetesinzidenz
Klein, F. (2018) · Info Diabetologie · doi:10.1007/s15034-018-1416-z
Cardiology update: 3 rd quarter
Farooqui, F. A., & Singh, S. (2018) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_66_18
Day, C. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.199
Singh, A. (2019) · Heart India · doi:10.4103/heartindia.heartindia_10_19
Treating the Brain But Forgetting the Heart: Mitral Valvular Disease Cabergoline Induced
Tabbah, R. N., el Bayeh, H., & Karaminassian, R. (2019) · Cardiology and Cardiovascular Research · doi:10.11648/j.ccr.20190303.14
Body Fat and Fitness for Ventricular Assist Device Therapy
Stewart, G. C. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.01.021
Writers, A. M. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00714-0
[Primary health care in Ghana, Africa. Report on a development aid program in health care].
Reifenrath, W. (1988) · PubMed
Supportive Component of Treatment: Medications for Treating Obesity
Golden, A. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-48683-9_11
Xi, Z., Gong, X., Li, B., Zhang, L., Pu, J. Y., Li, Y., Xu, Y., & Zhang, M. (2020) · PubMed Central · doi:10.7507/1001-5515.202008001 · Cited by 1
REVISÃO DA EFICÁCIA DO USO DA LORCASSERINA PARA A PERDA DE PESO
Camêlo, L. B., & Santos, M. N. (2021) · Revista interdisciplinar em saúde · doi:10.35621/23587490.v8.n1.p617-627
Defining Your Shape: The Determinants of Body Fat Distribution
Denton, N. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198865278.003.0007
Dietary and Medical Management of Obesity
Wilding, J. P. H., & Lim, J. Z. M. (2022) · doi:10.1093/med/9780198870197.003.0225
Sattar, N. A. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch14
Lorcaserin: no increased risk of cardiovascular events
(2018) · Reactions Weekly · doi:10.1007/s40278-018-51350-y
The pharmacological treatment of obesity: A historical perspective
Cuenca-Ecuador., U. C. D. C., Pacheco, A. V. G., Peláez, C. E. A., & Ortíz, R. (2022) · Gaceta Médica de Caracas · doi:10.47307/gmc.2022.130.s3.27
The Role of Community Pharmacy and Pharmacotherapy in Obesity Management
Maguire, T. A. (2022) · In clinical practice · doi:10.1007/978-3-030-83399-2_9
Managing Stable Coronary Artery Disease in Diabetes
Koulouridis, I., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_23
An Atherothrombotic Risk Score for Patients With Diabetes
Brummel, K. S., & Eagle, K. A. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.032
Posada, N. A. D. (2023) · doi:10.29375/tesis.19640 · Cited by 1
General Treatment of Pediatric Obesity
Benavent, M. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-26727-7_9
Obesity and Current Treatment Approaches: A Comprehensive Review
Mathialagan, K., Madhumitha, R., Muralidharan, K., & Jang, S.-J. (2024) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00040 · Cited by 1
Pharmacotherapy for Obesity: Recent Evolution and Implications for Cardiovascular Risk Reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_13
Sharma, D., Madaan, K., Jawanda, I. K., Soni, T., KOUL, K., Singh, P., & KUMARI, S. (2024) · Preprints.org · doi:10.20944/preprints202408.1806.v1
Updates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004 · Cited by 1
Central Modulators of Appetite in Eating Disorders
Procházková, P., Roubalová, R., & Papežová, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-46096-8_112
Şimşek, C., & Thompson, C. C. (2024) · Springer eBooks · doi:10.1007/978-3-031-70004-0_3
Cardiovascular safety of fixed-dose extended-release naltrexone/bupropion in clinical practice
Kyle, M., Burns, D., Murray, C. R., Watson, H. N., Swaney, J., Spevack, S. C., Leonhard, M. J., Simon, M. S., Moynihan, E., Lapane, K. L., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100169 · Cited by 1
“The findings of the emulation analysis in the EHR data were consistent with evidence from the CAMELLIA-TIMI 61 trial [7].”
InfluentialPharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Thiesmeier, R., Haller, P. M., Patel, S. M., Bohula, E. A., Morrow, D. A., Murphy, S. A., O’Donoghue, M. L., Sabatine, M. S., Scirica, B. S., Bhatt, D. L., et al. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf226
Self-citationРоль глифлозинов в терапии синдрома висцерального ожирения.2021.pdf
Doe, J. (2021) · Figshare · doi:10.6084/m9.figshare.14299100
Suresh, K., Holtrop, J. S., Dickinson, L. M., Willems, E., Smith, P. C., Gritz, R. M., & Perreault, L. (2022) · Figshare · doi:10.6084/m9.figshare.18132294
Ramirez-Cisneros, A., de Piñeres, V. G., Tamayo-Torres, C. S., Stefanakis, K., Angelidi, A. M., Fu, L., Anastasiou, G., & Mantzoros, C. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70496
Anti-obesity drugs: comprehensive review and emerging therapies
Marne, P., Patil, S. D., Vora, A., MohdSiddique, M. U., Gadkari, Y. U., & Kurkute, P. (2026) · Endocrine · doi:10.1007/s12020-025-04528-w · Cited by 1
“When compared to a placebo, lorcaserin was successful in promoting long-term weight loss in a high-risk group without raising the incidence of significant cardiovas - cular events [137].”
Incorporating Economic Evidence in Clinical Guidelines
Musher, D. M. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-04817
Prevention of Heart Failure in People With Diabetes
Pandey, A., & Hernandez, A. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00015-x
Lopez, D. S., Abdelgadir, O., Zhang, Y., Hernández‐Pérez, J. G., Hussain, M. R., Albayyaa, M., Nair, R., KUO, Y.-F., Almandoz, J. P., Cowell, L. G., et al. (2026) · Obesity · doi:10.1002/oby.70211
“Similar previous findings were observed with the incidence of CVD [16, 29, 36].”
Teli, B., Sathe, S., Kalra, R., Mahajan, V., Mehta, A., Shinde, R., Kunwar, B., Kahale, P., Sinkar, A., Palimkar, P., et al. (2026) · Cureus · doi:10.7759/cureus.111322
“Sibutramine in SCOUT was associated with an increased risk of CV events (HR 1.16), while rimonabant in CRESCENDO (HR 0.97), naltrexone/bupropion in LIGHT/CONVENE, and lorcaserin in CAMELLIA-TIMI (HR 0.97) did not demonstrate significant MACE reduction [19-21 , 23”
InfluentialChen, F., Chu, X., Zong, C., Yang, J., Yu, C., & Zhu, B. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/1108381
Diabetes mellitus and antithrombotic therapy: a systematic review
Μανές, Π. Α. (2026) · University of Thessaly Institutional Repository (University of Thessaly)
Almahmeed, W. A., Barajas-Gamboa, J. S., Zubaid, M., Al‐Ozairi, E., Shehab, A., Al‐Rasadi, K., Khalil, C. A., Busaidi, N. A., Sindi, F. A., Awan, Z. A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70204
Corrado, R., Raffa, S. D., Bauer, E. M., Eisenberg, D., Weare-Regales, N., Antonovich, N., Loblack, A., Berdiel, E., Kelber, M. S., Klimovich, J., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00676
The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
Halpern, B., Baur, L. A., Blüher, M., Jackson-Morris, A. M., Ralston, J., & Ryan, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00234-2 · Cited by 1
Metadata
- Authors
- Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., Garcia-Castillo, A., Gupta, M., Leiter, L. A., Weissman, N. J., White, H. D., Patel, T., Francis, B., Miao, W., Perdomo, C., Dhadda, S., Bonaca, M. P., Ruff, C. T., Keech, A. C., Smith, S. R., Sabatine, M. S., & Scirica, B. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston (E.A.B., S.D.W., J.K., K.I., A.Q., M.P.B., C.T.R., M.S.S., B.M.S.); the Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas (D.K.M.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); the Department of Medicine, University of Minnesota, Minneapolis (C.L.F.); the Partners Clinical Research Centre, Nassau,...
- ORCID
- Bohula, Erin A.
- Wiviott, Stephen D.
- McGuire, Darren K.
- Inzucchi, Silvio E.
- Kuder, Julia
- Fanola, Christina L.
- Qamar, Arman
- Budaj, Andrzej
- Gupta, Milan
- Leiter, Lawrence A.
- White, Harvey D.
- Patel, Tushar
- Perdomo, Carlos
- Dhadda, Shobha
- Bonaca, Marc P.
- Ruff, Christian T.
- Keech, Anthony C.
- Smith, Steven R.
- Sabatine, Marc S.
- Scirica, Benjamin M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-09-20
- Volume
- 379
- Issue
- 12
- Pages
- 1107-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2888628330
- Cited by
- 265
- References
- 28
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 20 · 2023: 32 · 2022: 30 · 2021: 36 · 2020: 41 · 2019: 57 · 2018: 18
- FWCI
- 24.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eisai
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- lorcaserin, cardiovascular safety, obesity, overweight, weight loss, appetite suppressants, major adverse cardiovascular events, non-inferiority, heart failure, hypoglycemia, atherosclerotic cardiovascular disease, weight management, adverse events, serious adverse events, cardiovascular risk factors, coronary revascularization, myocardial infarction
- MeSH terms
- Aged, Aortic Valve Insufficiency, Benzazepines, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Pulmonary, Hypoglycemia, Male, Middle Aged, Obesity, Risk Factors, Weight Loss, Anti-Obesity Agents, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.